By Fineline Cube 
China Resources Medical Holdings Company Limited has entered into a strategic partnership with Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366) in the medical aesthetics sector. The collaboration aims to establish an integrated “R&D-Production-Distribution” value chain.
Partnership Synergy
The partnership combines China Resources Medical’s extensive nationwide OTC distribution network, which covers 28 provincial-level regions across China, with Haohai Bio’s robust industrial production base. This synergy is expected to enhance their competitive edge in the high-growth, high-margin medical aesthetics market.
Strategic Direction
The medical aesthetics field has emerged as a critical strategic direction for traditional pharmaceutical companies undergoing transformation. Haohai Bio, one of China’s leading hyaluronic acid producers, demonstrated its strong market position with a remarkable gross margin of 77.47% on its medical aesthetics products last fiscal year.-Fineline Info & Tech